This product is no longer in stock
HEMOFIL M Antihemophilic Factor (Human) (AHF), Method M, Monoclonal Purified, is a sterile, non-fever causing, dried formulation of the following 3 factors involved in treating hemophilia, which are Factor VIII, Factor VIII:C and AHF. They are in concentrated form, with a specific range of activity of 2 to 22 AHF International Units/mg of total protein. This medication contains a maximum quantity of 12.5 mg/mL of albumin. Per AHF International Unit it contains 0.07 mg polyethylene glycol (3350) and 0.39 mg of histidine to serve as agents for stabilization. It does not contain more than 0.1 mg of glycine, 0.1 ng of mouse protein, 18 ng of organic solvent (in this formulation, tri-n-butyl phosphate) and 50 ng of detergent (in this formulation, octoxynol 9). When Albumin (Human) is not added to the formula, the specific activity for this medication is approximately 2,000 AHF International Units/mg of protein.
The antihemophilic factor (AHF) is a protein normally found in human plasma. This factor is essential to the clotting process. Giving HEMOFIL M AHF to a patient causes an increase in plasma levels of AHF that can temporarily correct the defect in coagulation in patients with hemophilia A, also known as classic hemophilia. Giving HEMOFIL M AHF to a patient will also correct the deficiencies brought on by circulating inhibitors, when the level of the inhibitor does not exceed 10 Bethesda Units per mL.
This medication should not be used in patients with a known hypersensitivity to the active substance, to the excipients, or to mouse proteins.
Reported side effects include: inflammation at site of infusion, headache, dysgeusia, factor VIII inhibition, dizziness and pyrexia.
Baxter Healthcare Corporation, California, USA
Also known as: Emoclot, Nuwiq, Koate-DVI, Octanate, Immunate, Wilate, Novoeight, Frozen Factor VIII, Recombinate, Kovaltry, Xyntha, Afstyla, Beriate